Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Liabilities and Shareholders Equity (2018 - 2025)

TransMedics (TMDX) has 8 years of Liabilities and Shareholders Equity data on record, last reported at $1.1 billion in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 32.87% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $3.7 billion, up 21.82%, while the annual FY2025 figure was $1.1 billion, 32.87% up from the prior year.
  • Liabilities and Shareholders Equity reached $1.1 billion in Q4 2025 per TMDX's latest filing, up from $946.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q4 2025 and bottomed at $117.3 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $526.6 million, with a median of $689.8 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 17.68% in 2021, then soared 488.62% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $134.9 million in 2021, then skyrocketed by 105.46% to $277.1 million in 2022, then soared by 154.76% to $706.0 million in 2023, then rose by 13.88% to $804.1 million in 2024, then surged by 32.87% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.1 billion in Q4 2025, $946.0 million in Q3 2025, and $890.5 million in Q2 2025.